This page holds a finished NR 601 Week 5 deprescribing write-up, from the full medicine list and its indications to the taper, the monitoring and the conversation with the patient. Searches like "nr 601 week 5 assignment example", "nr601 week 5 sample" and "nr 601 week 5 example" land here.
What a finished NR 601 Week 5 deprescribing write-up looks like
A completed write-up looks like an audit that ends in a decision. Every agent is listed with the indication it is being taken for, and the ones with no indication left are visible immediately: the proton pump inhibitor started in hospital four years ago, the sedative prescribed for two weeks and renewed ever since, the second agent added to treat the side effect of the first. Anticholinergic burden is totaled rather than mentioned, because three modest contributors produce the confusion no single one explains. The write-up then stops one or two things, not eight, tapering whichever agent punishes an abrupt stop, a date for review, and a plain sentence for the patient about why a medicine they have taken for years is being withdrawn now.
How a NR 601 Week 5 example is structured
Formats differ, and most sections want the list before the argument. It opens with every agent the patient takes, prescribed and otherwise, with dose, how long it has been running and who started it. An indication column comes next, and the blanks in that column do most of the work of the paper. Risk follows: which agents are known to cause harm in older adults, which are duplicated, which are treating another drug's effect, and what the total anticholinergic and sedative load comes to. The candidates are then ranked, harm against remaining benefit, with time to benefit weighed against how long this patient is likely to be around to collect it. One or two are chosen. A taper, a monitoring plan with dates, and the patient conversation close the document.
Everything the patient takes
Prescriptions plus drops, inhalers, supplements, laxatives and anything bought at a pharmacy counter, with dose, duration and the prescriber who began it recorded beside each.
An indication for every line
The reason each agent is still being taken, written out, because the empty spaces in this column are the paper's most useful finding.
Burden added up
Sedative and anticholinergic load totaled across the whole list rather than judged drug by drug, since the harm comes from the sum of small contributions.
One or two chosen, with reasons
The agents coming off, ranked by harm against remaining benefit, with time to benefit weighed against what this patient realistically has ahead of them.
Taper, monitoring and the conversation
How the withdrawal is staged, what is watched for and when, and the sentence said aloud to a patient who has taken the tablet for years.
Where marks go in NR 601 Week 5
The expensive failure is a paper that identifies the problem drugs and then stops nothing. It reads as an inventory, and inventories are not clinical acts. Close behind is the opposite error, a clean sweep that discontinues five agents at one visit with no order of operations, which no prescriber could monitor and no patient would tolerate. After those: a stop with no taper where a taper is standard, no monitoring interval attached to the withdrawal, the supplements and over the counter agents omitted from the list entirely, no acknowledgment that another prescriber started the medicine and will have to be told, the patient's own attachment to a long standing tablet unaddressed, and a recommendation with nothing cited behind it.
Get a NR 601 Week 5 example written to your instructions
Send the Week 5 medicine list and whatever your classroom published about the assignment, and a custom write-up is returned inside 24 to 48 hours with the first one free. It will show the indication audit, the ranking that produced the choice, and the taper written out rather than assumed.
NR 601 Week 5 questions, answered
Which tool should the write-up use?
Sections name their own, and several established explicit criteria lists for older adults are in common use at this level. Name the tool you applied, then apply it to this patient rather than reproducing its table. A criterion flagged and then reasoned about, including the case for keeping an agent the list warns against, scores better than a screenshot of the tool.
What if a specialist started the medicine?
That belongs in the write-up rather than being a reason to skip the agent. Say who prescribed it, what the original indication was, whether it still holds, and how the recommendation would be communicated to that prescriber. Deprescribing across clinicians is mostly a communication problem, and a paper that shows the message being sent is stronger than one that assumes agreement.
Is it ever right to leave a risky drug in place?
Yes, and saying so with reasons is often the strongest paragraph in the paper. A tablet that keeps somebody sleeping, walking or eating may be worth its risk when the alternative is a fall in function nobody wanted. What is required is the same standard applied in both directions, so keeping it is argued rather than simply left unexamined.